PGNYProgyny, Inc.
Price
+29%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, undemanding price, growing in the filings, the market undecided.
Progyny is a global leader in women’s health and family building solutions. We envision a world where everyone can realize their dreams of family and ideal health. Our mission is to empower healthier, supported journeys through transformative fertility, family building and women’s health benefits. Through our differentiated approach to benefits plan design, member education and support and active network management, our clients’ employees are able to pursue the most effective treatment across life’s milestones from the best providers and specialists and achieve optimal outcomes.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Progyny, Inc. (PGNY) reported revenue of $351M in Q2 2026 (quarter ended Jun 30, 2026), up 5.3% from the same quarter a year earlier. That came with a gross margin of 25% and net income of $28M (8.0% of revenue). For the full year FY2025, revenue was $1.29B (+10% year on year) and net income $59M. Its largest product in Q2 2026 was Fertility Benefit Services at $230M, 66% of the disclosed total, well ahead of Pharmacy Benefit Services at 34%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Progyny, Inc. Announces Second Quarter 2026 Results.Earnings release · press release
- May 27, 2026Progyny, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 21, 2026. At the Annual Meeting, the Company’s stockholders approved certain amendments (the “Charter Amendments”) to the Company’s Certificate of Incorporation.Charter/bylaw amendment or fiscal-year change · Form 8-K
- May 26, 2026Progyny, Inc. (the “Company”) announced today that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $350.5MThe company’s own SEC segment disclosure.
- Fertility Benefit Services$230.2M66%
- Pharmacy Benefit Services$120.3M34%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.